BCR and breast adenocarcinoma: The procedure of data integration is schematically presented in Figure 1 for a combination of breast adenocarcinoma cell line MDA-MB-468 originated from a 51 years old female sample [25], and dasatinib, a dual kinase inhibitor against BCR/ABL and SRC families of tyrosine kinases [26] primarily used to treat chronic myelogenous leukemia and acute lymphoblastic leukemia [27].